It was reported that short interfering RNA (siRNA) of EWS/Fli-1 downregulated phospholipase D (PLD)2 in Ewing's sarcoma (EWS) cell line, suggesting that PLD2 is the target of aberrant transcription factor, EWS/Fli-1. Here, we further investigated the regulation of PLD2 gene expression by EWS/Fli-1 and Fli-1 in another EWS cell line, and also in EWS/Fli-1-or Fli-1-transfected cell line. EWS/Fli-1-or Fli-1-overexpressed cells showed higher PLD2 but not PLD1 protein expression and enhanced cell proliferation as compared to mock transfectant. The treatment of these cells with 1-butanol or siRNA of PLD2 inhibited cell growth, suggesting the pivotal role of PLD in cell growth promotion. PLD2 but not PLD1 mRNA level was also increased in EWS/Fli-1 or Fli-1-transfectants. After determining the transcription initiation points, we cloned the 5 0 promoter of both PLD1 and PLD2 and analysed promoter activities. Results showed that EWS/ Fli-1 and Fli-1 increase PLD2 gene expression by binding to an erythroblast transformation-specific domain (À126 to À120 bp from the transcription initiation site) of PLD2 promoter, which is the minimal and most powerful region. Electrophoresis mobility shift assay using truncated proteins showed that both DNA-binding domain and trans-activating domain were necessary for the enhanced gene expression of PLD2.
Introduction
Ewing's family tumors, which include Ewing's sarcoma (EWS) and primitive neuroectodermal tumor, are the second most common bone and soft tissue tumor in childhood and adolescence after osteosarcoma (Ramugounder et al., 2004) . In EWS, chromosomal translocation produce fusion gene, EWS/Fli-1 or EWS/ERG, respectively (Delattre et al., 1992; Arvand and Denny, 2001 ). Fli-1 and ERG gene are members of the erythroblast transformation-specific (ETS) family of transcription factors.
A characteristic feature of this family is that they share the evolutionary-conserved ETS domain of about 85 amino-acid residues that mediate binding to purinerich DNA sequences with a central GGAA/T core consensus and additional flanking nucleotides (Graves and Petersen, 1998) . Functional characterization of EWS/Fli-1 has suggested that it acts as sequence-specific transcriptional activator (Dauphinot et al., 2001) . EWS/ Fli-1 is more potent in transcriptional activity than the wild type of Fli-1 in several promoters. These differences might be due to cooperation with other transcription factors and co-factors involving different DNA sequences in the regulatory region on the target genes (Oikawa, 2004) .
The target of potent transcription factor, EWS/Fli-1, has not yet been surveyed completely even with the use of DNA microarray (Prieur et al., 2004) . EWS/Fli-1 but not Fli-1 can transform NIH3T3 cells as well as murine primary bone-derived cells (Truong and Ben-David, 2000) . Antagonizing EWS/Fli-1 gene expression in tumors results in reduced tumorigenicity and clonogenicity (Toretsky et al., 1997) .
Phospholipase D (PLD) is a member of phospholipidsignaling enzymes, which cleave phosphatidylcholine (PC) and produce phosphatidic acid (PA). PLD has been known to be implicated in various cellular processes (Exton, 2002; Foster and Xu, 2003) . A role for PLD in cell proliferation is also suggested from previous reports showing the elevated PLD activity in response to various growth factors and sphingosine 1-phosphate (Liscovitch et al., 2000) . It has been reported that PLD activity is elevated in cells transformed by various oncogenes such as v-Ras, suggesting a potential role of PLD in oncogenesis (Carnero et al., 1994) . PLD has two isozymes, PLD1 and PLD2.
Despite abundant information regarding involvement of PLD activity in cell function, its precise role and regulatory mechanism of gene expression are not fully understood.
A recent report has demonstrated that the inhibition of EWS/Fli-1 by using short interfering RNA (siRNA) downregulates PLD2 protein expression, resulting in the repression of platelet-derived growth factor-mediated cell growth signaling in EWS cells (Nozawa et al., 2005) . We have extended this work by analysing the relationship between PLD gene expression and EWS/Fli-1 or Fli-1. Here, we report that EWS/Fli-1 and Fli-1 increase PLD2 but not PLD1 gene expression, thereby suggesting that in EWS, the transcription of PLD2 but not PLD1 is regulated by the direct interaction of the EWS/ Fli-1 with one ETS domain of 5 0 -PLD2 promoter. The distinct regulatory mechanism of PLD1 and PLD2 via the ETS transcription factor is also discussed.
Results
Elevated PLD2 but not PLD1 expression in EWS cell lines and DNA transfectants of EWS/Fli-1 or Fli-1 Figure 1 showed that PLD1 and PLD2 were detected in both EWS cell lines, TC135 and NCR-EW2, and EWS/ Fli-1 or Fli-1 transfectants (two representative clones) of SH-SY5Y cells. The PLD2 but not the PLD1 protein level was increased in these EWS cell lines and in EWS/ Fli-1 or Fli-1 transfectants, whereas non-EWS cell line, HEK293 and mock transfectants of SH-SY5Y cells did not show such increased PLD2 expression, thus suggesting that EWS/Fli-1 or Fli-1 induced elevation of PLD2 protein expression. Figure 2a illustrates the increase of basal PLD activity in EWS/Fli-1 and Fli-1 transfectants but not in mock transfectants. The message level of PLD2 also showed the comparable increases in these EWS cell lines and EWS/Fli-1 and Fli-1 DNA transfectants (Figures 2b and 2c ). Other subclones, EWS/Fli-1 sc4 and Fli-1 sc2, also showed increased PLD2 message (data not shown). The cell proliferation was examined in EWS/Fli-1-or Fli-1-transfected SH-SY5Y cells, showing that overexpression of EWS/Fli-1 and Fli-1 induced enhanced proliferation (Figure 3a) . However, the pretreatment of these cells with 1-butanol that prevents the production of PA by PLD, completely blocked this enhancing effect on cell growth. In contrast, t-butanol that is inactive for PLD inhibition was without effect in cell proliferation. Specific reduction of PLD2 message was observed by using siRNA of EWS gene in Ewing cell lines, TC135 Figure 3 Cell growth of EWS/Fli-1 or Fli-1 transfectants. (a) Cell growth of each cell line was shown by WST-1 assay on day 2 after cell culture in the presence or absence of 0.3% of 1-butanol or t-butanol. Initial cell density of each cell line was regarded as 1.0. Relative cell proliferation is expressed as the mean7s.d. from at least three different experiments. (b) Effect of siRNA of EWS was analysed using TC135 and NCR-EW2 cells. Cells were treated with or without siRNA of EWS or scramble siRNA. Two days after treatment, relative cell proliferation was measured as shown in (a). *Po0.01 (c) Effect of siRNA of PLD2 on cell proliferation was analysed using Fli-1-overexpressed SH-SY5Y sc5 cells. Cells were treated with or without siRNA of PLD2 or scramble siRNA. Two days after treatment, relative cell proliferation was measured. *Po0.01 (d and e) Effect of siRNAs (of EWS or PLD2) on hPLD1, hPLD2 and GAPDH message was examined by semi-quantitative RT-PCR as shown in Figure 2 . PCR cycle of PLD1, PLD2 and GAPDH shown in the figure were 28, 26 and 20, respectively, except 30 hPLD1 cycles of TC135 cells.
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and NCR-EW2 ( Figure 3d ). This treatment also inhibited cell proliferation ( Figure 3b ). Furthermore, siRNA of PLD2 inhibited not only PLD2 gene expression ( Figure 3e ) but also cell proliferation of Fli-1-overexpressed SH-SY5Y cells ( Figure 3c ). These results suggested that PLD2 plays an important role in cell proliferation of EWS/Fli-1-and Fli-1-overexpressed cells.
Determination of PLD 1 and PLD2 transcription initiation point in SH-SY5Y cells and cloning of PLD promoter The transcription initiation point of PLD1 and PLD2 in SH-SY5Y cells was shown in Figure 4a . We found multiple transcription initiation points of both PLD1 and PLD2, although they were not far from the reported initiation point. Based on these data, the promoter regions of PLD1 and PLD2 were cloned with the polymerase chain reaction (PCR)-based method. Figure 4a also illustrates the promoter regions of PLD1 and PLD2 that we analysed in the current study.
Increased PLD2 promoter activity in EWS/Fli-1 and Fli-1 transfectants By using various lengths of the promoter of PLD1, it was observed that among the stable transfectants of EWS/Fli-1, Fli-1 and mock-expression vector, PLD1 did not show significant differences in promoter activity (Figure 4b upper part), except for a small increase in the region between À1600 and À1344 bp. On the contrary, both EWS/Fli-1 and Fli-1 transfection resulted in enhanced promoter activity of PLD2 (Figures 4b lower part). Both EWS/Fli-1 and Fli-1 showed significant promoter activity in À198 PLD2 luc promoter construct. Truncation of PLD2 promoter disclosed that the region between À126 and À120 bp from the transcription initiation point was the minimal and most powerful EWS/Fli-1 or Fli-1 responsive promoter ( Figure 5a ). EWS/Fli-1 and Fli-1 are ETS proteins, and this specified region contains one putative ETS binding motif ( Figure 5b ). Therefore, we further investigated this small region. 
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Interaction of EWS/Fli-1 and Fli-1 with ETS protein binding site motif of PLD2 promoter Figure 5c illustrates the results of electrophoresis mobility shift assay (EMSA) by using nuclear extracts from various cell types. It was shown that TC135 and NCR-EW2 cells as well as EWS/Fli-1 or Fli-1 transfectants contained transcription factors binding to the ETS protein binding site (EBS) motif, whereas mock transfected SH-SY5Y cells did not. Addition of a cold competitor resulted in the disappearance of two shifted bands, indicating the specificity of these bands (Figure 6a ). Figure 6b shows the effect of anti-Fli-1 antibody (recognizing the ETS domain of both Fli-1 and EWS/Fli-1), demonstrating that two bands disappeared by addition of anti-Fli-1 antibody. This strongly suggests that two ETS binding proteins, EWS/Fli-1 and Fli-1, bind to this sequence. Further, we examined the effect of anti-EWS antibody, which recognizes N-terminal of EWS. Addition of this antibody only caused the disappearance of the bands formed in EWS/ Fli-1-overexpressed cells, confirming the specificity of Figure 6d shows the effect of mutation in this EBS motif. The mutated probe did not induce the appearance of the bands. Figure 7a depicts the truncated forms of Fli-1 and EWS/ Fli-1 that were used as the co-transfection vector for the promoter analysis (Figure 7b ) as well as nuclear protein preparation for EMSA (Figure 7c) . The promoter analysis shown in Figure 7b suggests that both the trans-activation domain (N-terminal) and the DNAbinding domain (C-terminal) are necessary for the enhanced promoter activity of PLD2. However, PLD1 promoter activity was not changed in various expression vector constructs (Figure 7b left) The binding profile of EMSA shown indicates that the binding site is the DNA binding domain located in the C-terminal of either EWS/Fli-1 or Fli-1, because Fli-1 (C), Fli-1 and EWS/ Fli-1 only showed the formation of two bands (Figure 7c ). Figure 8 shows the results of chromatin immunoprecipitation (CHIP) assay in both EWS/Fli-1-and SH-SY5Y cells were transfected with cDNA expression vectors described in (a). On day 2 after transfection, nuclear protein was prepared. The same wild-type probe for EMSA was used as shown in Figure 5 .
Anti-Fli-1 or anti-EWS antibody immunoprecipitates ETS binding domain of PLD2 promoter through Fli-1 or EWS/Fli-1 protein
Figure 8 CHIP assay. CHIP assay was performed in mock-, EWS/ Fli-1-or Fli-1-transfected SH-SY5Y cells as described in Materials and methods. Normal IgG, anti-Fli-1 antibody or anti-EWS antibody was used for the immunoprecipitation. The expected PCR product was 144 bp covering the 5 0 -promoter region between À137 and þ 7 of PLD2 where the ETS binding motif is located. A schematic illustration of CHIP assay was shown in Figure 8b .
Mechanism of PLD2 gene expression induced with EWS/Fli-1 R Kikuchi et al
Fli-1-transfected SH-SY5Y cells. Although mock transfectant did not reveal any band formation, anti-Fli-1 antibody but not normal immunoglobulin (Ig)G could immunoprecipitate the EWS/Fli-1 fusion protein and Fli-1 protein, which bind to the PLD2 promoter, whereas anti-EWS antibody only immunoprecipitated EWS/Fli-1 protein bound to the PLD2 promoter.
Discussion
The role of PLD in cell growth and oncogenesis is well known because PLD activity is elevated in response to various factors (Exton, 2002) . There are many reports demonstrating that, in various tumor cells, the activities and protein expressions of PLD1 or PLD2 are elevated (Foster and Xu, 2003) . These studies suggest that increased PLD expression plays a role in cell proliferation and differentiation. However, an analysis did not serve to elucidate the regulatory mechanism of the gene expression.
A recent study showed that the reduced EWS/Fli-1 expression by using siRNA induces downregulation of PLD2 protein expression (Nozawa et al., 2005) . However, the mechanism of PLD2 gene expression by EWS/ Fli-1 was not studied. In the present study, we have investigated the precise mechanism of EWS/Fli-1-promoted PLD2 gene expression in EWS cell lines. Although the analysis of murine PLD1 and PLD2 gene organization was reported previously (Redina and Frohman, 1998a, b) , the promoter analysis of either PLD1 or PLD2 has not yet been reported. Here, we described for the first time a promoter analysis based on the consistent increase of hPLD2 mRNA, hPLD2 protein and PLD activity by overexpression of EWS/ Fli-1 or Fli-1.
Fli-1 belongs to the ETS family transcription factor and is the major target for gene translocation in human EWS. Examination of the DNA-binding properties of Fli-1 and EWS/Fli-1 has revealed that both proteins recognize the same consensus DNA binding sequence which had previously been identified for Fli-1 (Mao et al., 1994) . It appears that the EWS/Fli-1 protein is a more potent trans-activator than the wild-type Fli-1 resulting in the enhanced expression of certain genes and ultimately uncontrolled cell growth (Truong and BenDavid, 2000) . However, in our study there was no significant difference in the enhancement of PLD2 gene expression between EWS/Fli-1 and Fli-1 transfectants as shown in Figure 1b . Sementchenko and Watson (2000) reviewed the targets of ETS protein including Fli-1, which may activate or suppress the transcription of GATA-1 in a cell-type-specific manner. Here, we have shown that PLD2 is a novel target of EWS/Fli-1 as well as of Fli-1 transcription factor and that one ETS binding site (À126 to À120 bp from the transcription initiation point) works as the principal promoter of PLD2 gene. From our EMSA analysis in combination with the promoter analysis, it was shown that both the trans-activation domain and the DNA-binding domain of ETS protein were indispensable for promoting the PLD2 transcription (Figures 7b and c) . We also observed that other ETS transcription factor, such as PU.1, ETS1 or ETS 2 could induce PLD2 gene expression in SH-SY5Y cells (data not shown), suggesting PLD2 as the general target of ETS protein family. The CHIP assay proved the specificity of our results, because a PCR band was observed in EWS/Fli-1 nuclear extract by either antiFli-1 or anti-EWS antibody, whereas a PCR band was observed in Fli-1-overexpressed cell nuclear extract by anti-Fli-1 antibody but not anti-EWS antibody. (Figures 8a and b) Deregulation of PLD expression and activity has also been reported in various human cancers (Zhao et al., 2000) . PLD activity is also elevated in cells transformed with various oncogenes such as ras (Carnero et al., 1994) . However, the precise role of two PLD isoforms in mitogenic signaling has not been elucidated. Our results clearly showed that increased PLD2 gene expression played a role in the proliferation of EWS cell lines and the EWS/Fli-1 or Fli-1 transfectants (Figures 1, 2  and 3 ). Our results also suggest that PLD2 is mainly involved in the increased PLD activity in EWS tumor (Figures 1 and 2) .
The regulation of each PLD isoform gene expression is thought to be cell type-specific. Our promoter analysis demonstrated that PLD1 gene expression was constitutive but not responsive to EWS/Fli-1 or Fli-1 transcription factors, whereas PLD2 expression is under the tight control of transcription factors, EWS/Fli-1 or Fli-1 (Figures 4 and 5) . It would be interesting to know why gene expression of PLD2 but not PLD1 was stimulated by EWS/Fli-1 or Fli-1 transcription factor, because the PLD1 promoter also has six candidate EBS motifs within À1.6 kb 5 0 promoter region (Figure 4a ). In our study, TC135 cell line showed predominant expression of PLD2, whereas PLD1 protein as well as gene expression was very weak (Figures 1 and 2 ). Our preliminary results have shown that trichostatin A, an inhibitor of histone deacetylase, could stimulate PLD1 gene expression of TC135 cells more than two times. The condition in histone acetylation around PLD1 genome is one of the possible mechanisms of the insensitivity of PLD1 transcription to ETS family protein. However, further analysis is needed.
Taken together, this study is the first, to our knowledge, to demonstrate a promoter analysis for human PLD1 and PLD2, and also to show that either EWS/ Fli-1 or Fli-1 stimulated PLD2 gene expression via a single ETS binding motif.
Materials and methods
Cell lines and reagents EWS cell lines, NCR-EW2 and TC135, were obtained from Dr H Ohkita (National Research Institute for Child Health and Development, Tokyo, Japan) and Dr T Ohno (Gifu University, Gifu, Japan), respectively. HEK293 cell was used as a non-EWS cell line. SH-SY5Y cell was obtained from Dr Y Akao (Gifu International Institute of Biotechnology, Gifu, Japan) and used for DNA transfection. EWS/Fli-1 and Fli-1 expression vectors were obtained from Dr O Delattre (Prieur et al., 2004) (INSERM U509, Paris, France) and Dr J Ghysdael (Institut Curie, Orsay, France), respectively. Fli-1 cDNA was cut out from the original vector and inserted into pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). The truncated fragments of EWS/Fli-1 used in this experiment are shown in Figure 7a , and all the vectors were based on pcDNA3.1. siRNA of PLD2 and of EWS were obtained from Sigma Genosys (Hokkaido, Japan). The sequence of siRNAs of EWS and of PLD2 was according to Nozawa et al. (2005) .
DNA transfection, establishment of stable transfectants and Western blotting DNA transfection was performed by a calcium precipitation method as described previously (Sobue et al., 2005) . Stable transfectants of SH-SY5Y cell were established by G418 selection. Suitable clones were checked by Western blotting using anti-Fli-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Two subclones showing the highest expression were used for further study. Anti-b-actin antibody was from Sigma (St Louis, MO, USA). Anti-EWS (N-18) and anti-Fli-1 (C-19) antibodies were from Santa Cruz Inc. (Santa Cruz, CA, USA). Anti-PLD1 and -PLD2 antibodies and Western blotting were described previously (Banno et al., 1999) .
Cell growth
Cell growth was determined with WST-1 assay kit (Roche Applied Science, Penzberg, Germany). Cells (2 Â 10 4 cells/well) in a 96-well plate were incubated under various conditions, and WST-1 reagent was added to the culture for 2 h. The absorbance at 450 nm was measured.
PLD enzyme activity
Total cellular PLD activity was determined by measuring the generation of 3 H-labeled choline from [choline-methyl-3 H] dipalmitoyl-PC without any activating factors as described previously (Banno et al., 1999) .
Semi-quantitative RT-PCR
Semi-quantitative reverse transcription (RT)-PCR was performed as described before (Nakade et al., 2003) . In the preliminary experiments, the suitable amounts of cDNA and the range of PCR cycles that permit the linear amplification of PLD1 and PLD2 were determined. As the internal control, glyceraldehydes-3-phosphate dehydrogenase (GAPDH) message was measured.
PLD1 primers were forward: 5 0 -AAAAGGAGCCACGGGT AAA-3 0 , reverse: 5 0 -ATTGGACGGCCGGAGAGA-3 0 . PLD2 primers were forward: 5 0 -GCTTGACTCACGGCGACTTTT-3 0 , reverse: 5 0 -AAAGGACTGGAGGGGATGATC-3 0 . GAPDH primers were forward: 5 0 -GTCAGCCGCATCTTCTTTTG-3 0 , reverse: 5 0 -CGCCAGCATCGCCCCACTTG-3 0 . The PCR conditions for human PLD1, PLD2 and GAPDH were 941C for 30 s, 601C for 30 s and 721C for 30 s. The number of cycles of PLD1, PLD2 and GAPDH were 26, 28 and 30; 24, 26 and 28; 18, 20 and 22, respectively . The band intensities of hPLD1 28 cycles, hPLD2 26 cycles and GAPDH 20 cycles were measured by NIH image version 6. The expression level of PLD1 and PLD2 was calculated and was shown as the ratio of PLD/GAPDH.
Rapid amplification of 5
0 cDNA ends The transcription initiation point of PLD1 and PLD2 was determined with RNA ligase-mediated rapid amplification method of 5 0 cDNA ends (5 0 RACE) by using a Gene Racer kit (Invitrogen). The reverse PLD1 and PLD2 gene-specific primers were 5 0 -TTTTATTGGACAGCCGGAGAGATAC-3 0 and 5 0 -GCGGACAGAATACAGAGTGCAGG-3 0 , respectively. The reverse PLD1 and PLD2 gene-specific nested primers were 5 0 -CACTTCTTGTATCTTGGGATCGCTGG-3 0 and 5 0 -TGTGACAGGGACCCCAGGTGCGAA-3 0 .
Cloning of PLD promoter region Originally, we obtained approximately 1.6 kb Mlu-I and Bgl-II fragment covering the 5 0 region of exon1 of PLD1 and 1.7 kb Mlu-I and Bgl-II fragment covering the 5 0 region of exon1 of PLD2 using the PCR method based on the human DNA sequence and our 5 0 RACE results. These fragments were inserted into the Mlu-I and Bgl-II sites of pGL3 basic vector, respectively (Promega, Madison, WI, USA), and used for promoter analysis.
Promoter analysis SH-SY5Y cells or its transfectants (2 Â 10 6 ) were transfected with 5 mg of reporter plasmid containing various lengths of the 5 0 promoter region of either hPLD1 or hPLD2 gene and 2 mg of b-galactosidase expression vector (Promega) using the calcium precipitation method. After 24 h, cell lysates were prepared. Promoter activity was normalized with the b-galactosidase activity. Truncated promoters of PLD1 and PLD2 were prepared with the PCR-based methods as shown in Figure 4 (further information available through the journal web site).
Electrophoresis mobility shift assay Nuclear extract was prepared from EWS cell lines, TC135 and NCR-EW2, and stable transfectants of EWS/Fli-1 or Fli-1 in SH-SY5Y cells. EMSA was performed according to the method described previously (Sobue et al., 2005) . For the supershift experiment, anti-Fli-1 (Santa Cruz Inc.) or anti-EWS antibody (Santa Cruz Inc.) was mixed with nuclear extract for 15 min at room temperature before mixing with the labeled probe as described below. Upper; 5 0 -AGACGAGAAT CCCGCGGAGGTGAGG-3 0 Lower; 5 0 -CCTCACCTCCGC GGGATTCTCGTCT-3 0 (underline: ETS binding motif).
Chromatin immuno-precipitation assay CHIP assay was performed as described previously (Sobue et al., 2005) . Mock-transfected SH-SY5Y, EWS/Fli-1-transfected SH-SY5Y and Fli-1-transfected SH-SY5Y cells were used for the crosslinking with formaldehyde. For the immunoprecipitation, normal rabbit IgG, anti-Fli-1-antibody (Santa Cruz, final concentration: 1 mg/ml) or anti-EWS antibody (Santa Cruz) was added and incubated for 4 h at 41C. Immunocomplexes were extracted, and crosslinking was reversed by heating the elutes at 651C overnight. The elutes were then digested with proteinase K at 501C for 5 h and extracted with phenol/chloroform/isoamyl alcohol. DNA was purified by ethanol precipitation. The PLD2 promoter region was amplified by PCR using primers 5 0 -ACAGGACAGACG AGAATCCCG-3 0 (forward) and 5 0 -AGCCAAGAGAGCAG ACCGCA-3 0 (reverse).
